Literature DB >> 18516058

IgA nephropathy: markers of progression and clues to pathogenesis.

A Rifai1, L D Dworkin.   

Abstract

The unpredictable progression of IgA nephropathy hinders its treatment. The correlation of renal dysfunction with the immunophenotype of leukocytic infiltrates revealed interstitial CD20(+) cells and tubular NKG7(+)(GMP-17(+))/CD8(+) intraepithelial cells as predictive markers of progression in early-phase IgA nephropathy. This suggests that adaptive and innate immune responses mediate progression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18516058     DOI: 10.1038/ki.2008.158

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  4 in total

1.  A proton nuclear magnetic resonance-based metabonomics study of metabolic profiling in immunoglobulin a nephropathy.

Authors:  Weiguo Sui; Liping Li; Wenti Che; Zuo Guimai; Jiejing Chen; Wuxian Li; Yong Dai
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

2.  NLRP3 inflammasome: Pathogenic role and potential therapeutic target for IgA nephropathy.

Authors:  Yu-Ling Tsai; Kuo-Feng Hua; Ann Chen; Chyou-Wei Wei; Wen-Shiang Chen; Cheng-Yeu Wu; Ching-Liang Chu; Yung-Luen Yu; Chia-Wen Lo; Shuk-Man Ka
Journal:  Sci Rep       Date:  2017-01-24       Impact factor: 4.379

3.  Immunoglobulin A (IgA) Nephropathy: A Clinicopathologic Study in a Tertiary Care Center in Saudi Arabia.

Authors:  Omar A Bokhary; Hanadi M Alhozali; Maha K Alghamdi; Ahmed M Abulfaraj; Abdulaziz S Alkhallagi; Abdulmohsen S Aldharrab; Faisal S Alyahya; Reem A Al Zahrani
Journal:  Cureus       Date:  2021-11-10

4.  Tris DBA ameliorates IgA nephropathy by blunting the activating signal of NLRP3 inflammasome through SIRT1- and SIRT3-mediated autophagy induction.

Authors:  Chung-Yao Wu; Kuo-Feng Hua; Shin-Ruen Yang; Yi-Shan Tsai; Shun-Min Yang; Chih-Yu Hsieh; Chia-Chao Wu; Jia-Feng Chang; Jack L Arbiser; Chiz-Tzung Chang; Ann Chen; Shuk-Man Ka
Journal:  J Cell Mol Med       Date:  2020-11-01       Impact factor: 5.295

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.